AI assistant
Olema Pharmaceuticals, Inc. — Director's Dealing 2026
Jan 16, 2026
32591_dirs_2026-01-15_9f699626-d714-4e9e-a529-dc0225c51898.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Olema Pharmaceuticals, Inc. (OLMA)
CIK: 0001750284
Period of Report: 2026-01-13
Reporting Person: Kovacs Shane William Charles (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-13 | Common Stock | S | 3822 | $28.01 | Disposed | 239727 | Direct |
| 2026-01-15 | Common Stock | S | 100000 | $28.73 | Disposed | 139727 | Direct |
Footnotes
F1: The weighted average sale price for the transaction reported was $28.01, and the range of prices were between $28.00 and $28.03. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
F2: The weighted average purchase price for the transaction reported was $28.73, and the range of prices were between $28.50 and $29.18. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price will be provided.